Researchers have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors.
View post:
Genetic variation that raises risk of serious complication linked to osteoporosis drugs identified
